Biomea Fusion reveals Phase 1 results for BMF-650, a new oral small molecule GLP-1 receptor agonist.

Observed price moves

• BMEA-30.57%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.